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ABSTRACT 
 
Mitochondrial dysfunction has been implicated in the aetiology of monogenic Parkinson’s disease (PD). 
Yet the role that mitochondrial processes play in the most common form of the disease; sporadic PD, is 
yet to be fully established.  Here we comprehensively assessed the role of mitochondrial function 
associated genes in sporadic PD by leveraging improvements in the scale and analysis of PD GWAS data 
with recent advances in our understanding of the genetics of mitochondrial disease.  First, we identified 
that a proportion of the “missing heritability” of the PD can be explained by common variation within 
genes implicated in mitochondrial disease (primary gene list)  and mitochondrial function (secondary gene 
list). Next we calculated a mitochondrial-specific polygenic risk score (PRS) and showed that cumulative 
small effect variants within both our primary and secondary gene lists are significantly associated with 
increased PD risk. Most significantly we further report that the PRS of the secondary mitochondrial gene 
list was significantly associated with later age at onset. Finally, to identify possible functional genomic 
associations we implemented Mendelian randomisation, which showed that 14 of these mitochondrial 
function associated genes showed functional consequence associated with PD risk. Further analysis 
suggested that the 14 identified genes are not only involved in mitophagy but implicate new mitochondrial 
processes. Our data suggests that therapeutics targeting mitochondrial bioenergetics and proteostasis 
pathways distinct from mitophagy could be beneficial to treating the early stage of PD.  
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INTRODUCTION  
  
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder characterized 
pathologically by the death of dopaminergic neurons in the substantia nigra (SN) and aggregation of α-
synuclein protein (encoded by SNCA), within intraneuronal inclusions called Lewy bodies. The majority of 
PD cases are apparently sporadic in nature (~95%). Aging is a major risk factor for the disease and due to 
population ageing the prevalence of PD is predicted to increase rapidly, making the identification of 
therapeutic targets a high priority1–3 . 
  
Although there have been great advances in understanding both the genetic architecture and cellular 
processes involved in PD, the exact molecular mechanisms that underlie PD remain unknown 1. However, 
it is suggested that PD has a complex etiology, involving several molecular pathways, and understanding 
these specific pathways will be key to establishing mechanistic targets for therapeutic intervention.  While 
several key pathways are currently being investigated, including autophagy, endocytosis, immune 
response and lysosomal function, 4–7 mitochondrial function was the first biological process to be 
associated with PD 8,9. 
  
An interest in mitochondrial function and PD began with the observation that exposure to the drug 1-
methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) can cause rapid parkinsonism and neuronal loss in 
the SN in humans, and that this is mediated through inhibition of complex I of the mitochondrial electron 
transport chain 7,10,11. Subsequent work suggested that individuals with sporadic PD have reduced 
complex I activity not only in the SN, but in other brain regions and peripheral tissues 12. Genetic studies 
focusing on monogenic forms of PD provided further support for the involvement of mitochondrial 
dysfunction in the disease. Pathogenic mutations that lead to autosomal recessive forms of PD have been 
reported in PINK1, PARK2, PARK7, CHCHD2 and VPS13C and the proteins they encode are all now known 
to be involved in the mitochondrial quality control system and in particular mitophagy 13–16.  
 
Therefore in this paper, we aim to comprehensively assess the role of mitochondrial function in sporadic 
PD by leveraging improvements in the scale and analysis of PD genome wide association study (GWAS) 
data with recent advances in our understanding of the genetics of mitochondrial disease.  The availability 
of large scale genome wide association data in PD cases and the rapid identification of genetic lesions that 
underlie mitochondrial disease provide an opportunity to systematically assess the role of genetic 
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variability in mitochondrial linked genes in the context of risk for PD17. In this study we combine these 
new resources with current statistical tools, such as polygenic risk scoring and Mendelian randomisation, 
to explore the role of mitochondrial function in both PD risk and age at onset of disease to obtain novel 
insights. 
 
RESULTS  
 
A component of the  “missing heritability” of PD lies within mitochondria function genes 
 
The general workflow for the genetic analysis used in this study is shown in Figure 1. First, to study the 
importance of mitochondrial function in sporadic PD, we investigated the heritability of PD specifically 
within genomic regions that contained genes annotated as important in mitochondrial function. The 
construction of this annotation was driven by the principle that genomic regions, which are known to be 
the sites of mutations in individuals with rare mitochondrial diseases or are candidate regions for such 
mutations provide the best evidence for involvement in mitochondrial function.  
 
Using GCTA, heritability estimates were first calculated for the four largest IPDGC GWAS datasets and 
including all variants (UK_GWAS, SPAIN3, NIA, DUTCH). Due to the low number of included cases, the 
heritability estimates in the other IPDGC datasets were deemed less reliable. Consistent with previous 
heritability estimates from both Keller and colleagues (2012; 24%) and Chang and colleagues (2017; 21%), 
our random effects meta-analysis for the four datasets identified 23% (95% CI 12-34, p= 2.72E-05) 
phenotypic variance associated with all PD samples (Table 1 & 2). There was a high degree of consistency 
across the cohorts. 
  
After establishing the consistency of our heritability estimates we next calculated heritability using only 
variants located within genic regions specified as being of primary (n=176) or secondary (n=1463) 
importance in mitochondrial function. Genes within the primary or secondary lists, which had already 
been identified in the most recent PD meta-analysis were excluded 6. The heritability estimate using a 
random-effects meta-analysis for the primary gene list was estimated to be a modest 0.26% (95% CI -0.11-
0.66, p=0.166). However, the heritability estimate using a random-effects meta-analysis for the secondary 
list, namely genes implicated in mitochondrial function or morphology as well as disease, was estimated 
to be 1.67% (95% CI -0.07-0.32, p=0.041).  
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Mitochondria function specific polygenic risk score is significantly associated with disease status  
 
Next, we calculated PRS to capture the addictive effect of all common variants within genes implicated in 
mitochondria function on PD risk. PRS is a particularly powerful approach in this context because it is able 
to efficiently incorporate information from all hits including sub-significant hits, which may nonetheless 
be etiologically relevant. 
 
Using this approach the primary and secondary mitochondrial genomic annotations were found to be 
significantly associated with PD disease status. Remarkably, the primary gene list consisting of only 176 
genes implicated in Mendelian mitochondrial disorders, was associated with PD with an odds ratio of 1.12 
per standard deviation increase in the PRS from the population mean (random-effects p-value = 6.00E-04, 
beta = 0.11, SE = 0.03).  The secondary gene list, which also included genes implicated in mitochondria 
function or morphology, was associated with PD with a higher odds ratio of 1.28 per standard deviation 
increase in the PRS from the population mean (random-effects p-value =1.9E-22, beta = 0.25, SE = 0.03) 
(Figure 2). Together, these analyses not only provide further support for importance of mitochondrial 
processes in PD, but potentially provide a tool for identifying PD patients most likely to benefit from 
treatments specifically targeting mitochondrial function. 
 
Mitochondria function-specific polygenic risk score is significantly associated with later age at onset 
 
Although multiple lines of evidence point to the importance of mitochondrial dysfunction as a primary 
cause of PD, impaired mitochondrial dynamics appears to be common to a wide range of 
neurodegenerative diseases including Huntington’s disease18,19, amyotrophic lateral sclerosis20,21 and 
Alzheimer’s disease22–25. The latter suggests that even when impaired mitochondrial function is not the 
primary event in disease pathogenesis, it is a common outcome and could contribute to disease 
progression. We sought to test this hypothesis by investigating the importance of common variation 
within our mitochondrial gene lists in determining the age at onset of PD (AAO). Given the significant lag 
period between PD pathophysiology and symptoms, AAO was used as an indirect measure of disease 
progression. This analysis was performed using PRS since it has been consistently found to be the main 
genetic predictor of AAO 6,2627,28 with higher genetic risk scores being significantly associated with an 
overall trend for earlier AAO of disease. While the primary mitochondrial gene list was not significantly 
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associated with AAO of disease, the secondary gene list was correlated with AAO. Contrary to expectation, 
the cumulative burden of common variants within the 1463 genes comprising the PRS for PD risk, were 
positively correlated with AAO of PD. After meta-analysing all 11 cohorts, we found that each 1SD increase 
in PRS, led to a 0.62 year increase in the AAO of disease (summary effect = 0.618, 95%CI (0.325-0.911),|2 
=61.33%, p-value=3.56E-05, Figure 3).  As the forest plots demonstrate, although there was a relatively 
high heterogeneity across studies, the directionality and magnitude of effect on AAO were in concordance 
with the meta-analysis with the exception of the Oslo cohort. This finding could suggest that firstly, 
disease causation and progression are genetically separable processes in PD and that secondly the role of 
mitochondrial dysfunction in PD is likely to be highly complex with multiple distinct mitochondrial 
processes likely to be involved at different disease stages. 
 
MR suggests potential causal association of fourteen novel mitochondria function genes with PD risk  
 
Given the robust evidence for the involvement of mitochondrial function in sporadic PD, next we used 
two sample MR analysis to identify specific genes likely to be important in PD risk. Since we wanted to 
identify novel associations, we excluded genes already linked to PD through the most recent GWAS meta-
analysis6. This resulted in the exclusion of 31 genes linked to mitochondrial function and in linkage 
disequilibrium with the top PD risk variants. Analysis of the remaining 1432 genes (generated by 
combining the primary and secondary gene lists) resulted in the identification of fourteen novel genes 
linked to mitochondrial function and causally associated with PD risk (Table 3). Of the fourteen genes, the 
expression of 5 genes (CLN8, MPI, LGALS3, CAPRIN2 and MUC1) was positively associated with PD risk in 
blood. Similarly, in brain PD risk was associated with increased expression of ATG14, E2F1, and EP300 in 
brain. However, negative associations in brain and blood expression were observed for MRPS34 and 
PTPN1 and LMBRD1 respectively. Finally, elevated methylation of FASN in the brain was found to be 
positively associated with PD risk but elevated methylation of CRY2 was found to be inversely correlated.  
 
Six of the fourteen novel PD risk genes we identified (CLN8, EP300, LMBRD1, MPI, MRPS34 and MUC1) 
are already associated with a monogenic disorder (Table 3). We noted that neurological abnormalities 
were a feature of the condition in five of the six cases with Combined Oxidative Phosphorylation 
Deficiency 32 due to biallelic mutations in MRPS34 being perhaps of particular interest. In common with 
PD, this condition is associated with abnormalities of movement, including dystonia and choreoathetoid 
movements. Mutations causing this condition result in decreased levels of MRPS34 protein causing 
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destabilisation of the small mitochondrial ribosome subunit and suggesting the involvement of 
mitochondrial processes distinct from mitophagy and mitochondrial homeostasis in PD. In this context, it 
is noteworthy that MRPL43, another nuclear gene encoding for a component of the large mitochondrial 
ribosome subunit is also highlighted by the MR analysis. Thus, this analysis not only enabled us to identify 
specific genes of interest, but also pointed to the role of multiple mitochondrial processes in PD distinct 
from mitophagy. 
 
  
Exploring the expression of the novel mitochondria risk genes provides additional support for their role 
in PD 
 
We leveraged publicly available cell-specific and tissue-specific gene expression data to investigate the 14 
mitochondria genes implicated in PD through MR. First, we used enrichment-weighted cell-type 
enrichment (EWCE) to determine whether the expression of mitochondrial PD-associated genes (as 
identified through MR and described above, n= 14) was enriched within a specific cell-type class or their 
subtypes. No significant enrichment of these genes was found in any of the tested neuronal and glial cell-
type classes (Supplementary Table 6, Supplementary Figure 1). Next, we used co-expression network 
analysis to identify possible functional interactions between the 14 novel mitochondrial genes identified 
through MR and genes implicated in monogenic forms of PD. We found that five of the 14 genes assessed, 
CLN8, FASN, MPI, MRPL43 and MRPS3, were highly co-expressed with at least one gene already implicated 
in monogenic PD in multiple brain regions (>3 brain regions, Supplementary Table 7). Interestingly, in the 
case of CLN8, MRPL43 and MRPS4, our novel genes were co-expressed with a monogenic PD gene already 
implicated in mitochondrial function such as PARK7. Furthermore, with the exception of CLN8, (FASN, 
MPI, MRPL43 and MRPS3), the novel mitochondrial gene was assigned to a co-expression module 
enriched for neuronal markers (Table 4, Supplementary Table 8). 
 
 
 
 
 
 
 
for use under a CC0 license. 
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available 
was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint (which. http://dx.doi.org/10.1101/475111doi: bioRxiv preprint first posted online Dec. 4, 2018; 
8 
DISCUSSION  
 
We first demonstrate that a proportion of  the “missing heritability” of sporadic PD can be explained by 
additive common genetic variation within genes implicated in mitochondrial disease and function, even 
after exclusion of genes previously linked to PD through linkage disequilibrium with the top risk variants 
4–6,29–33. In fact, using PRS, which efficiently incorporates information from sub-significant hits, we showed 
that cumulative small effect variants within only 196 genes linked to monogenic mitochondrial disease 
significantly associated with increased PD risk (with odds ratios of 1.12 per standard deviation increase in 
PRS from the population mean). These findings are important for two main reasons. Firstly, given that risk 
profiling performed in the recent PD meta-analysis did not identify a significant association with 
mitochondrial function 4–6,29–33 17. Secondly, since the primary gene list consisted solely of the 196 genes 
mutated in monogenic mitochondrial disorders, this analysis highlights the increasingly close relationship 
between Mendelian and complex disease7.  
 
In order to maximise the utility of this study, we used MR which identified 14 specific mitochondrial genes 
of interest with putative functional consequences in PD risk. We found that although a number of the 
genes we identified are clearly linked to known PD-related pathways, such as lysosomal dysfunction in the 
case of CLN8 and LMBRD1 or autophagy in the case of ATG14, others appeared to point towards new 
processes. In particular, this analysis highlighted the mitochondrial ribosome through the identification of 
the genes, MRPL43 and MRPS34, encoding components of the large and small mitochondrial ribosome 
subunits respectively. Interestingly, biallelic mutations in MRPS34 are known to cause a form of Leigh 
syndrome, characterised by neurodegeneration in infancy with dystonia and choreoathetoid movements 
due to basal ganglia dysfunction. Furthermore, we note that a recent study that utilized whole exome 
sequencing (WES) data from two PD cohorts to investigate rare variation in nuclear genes associated with 
distinct mitochondrial processes, not only provided support for the involvement of mitochondrial function 
in sporadic PD, but also identified the  gene, MRPL43,  which encodes a component of the large 
mitochondrial ribosomal subunit34. Interestingly, MRPL43 and MRPS34 were amongst five genes which 
were also highly co-expressed in human brain with genes already known to cause monogenic forms of PD. 
Whereas MRPL43 and MRPS34 were highly co-expressed with PARK7 in modules enriched for neuronal 
markers, FASN and MPI were co-expressed with ATP13A2, and CLN8 was located in modules containing 
FBXO7 and enriched for oligodendrocyte markers. While this form of analysis does not provide 
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information at the single cell level, it points to the possibility of pathway interactions between these gene 
sets. However, most importantly it implicates entirely distinct mitochondrial processes in PD risk.  
 
Finally, and perhaps most remarkably using our mitochondrial gene lists we observe clear differences 
between disease causation and AAO in PD. Although PRS of the primary mitochondrial gene list was not 
significantly associated with AAO, the PRS of the secondary mitochondrial gene list was positively 
correlated (p value =3.6E-05), indicating association with later age at onset.  However, given these findings 
it seems plausible that some mitochondrial processes may contribute to PD risk. Thus, this analysis is 
consistent with the findings of the most recent and largest AAO PD GWAS, which reported that not all the 
well-established risk loci are associated with AAO and suggested a different mechanisms for PD causation 
and AAO 35.  
 
Although in this study we have comprehensively analyzed the largest PD datasets currently available with 
very specific and inclusive mitochondrial function gene lists, there are a number of limitations to our 
analyses.  Firstly, there was a relative amount of heterogeneity in age at PD diagnosis within the AAO 
GWAS studies used. This was due to certain cohorts AAO being self-reported and other cohorts specifically 
recruiting younger onset cases. Nonetheless, the highly significant p-value we obtain for the association 
mitochondrial genes and AAO of PD (p-value=3.56E-05) and the recognized importance of mitochondrial 
function in aging would suggest that this finding is likely to be robust. Furthermore, it is important to 
recognize that our understanding of mitochondrial biology is far from complete and this is made evident 
by the fact that many individuals with probable genetic forms of mitochondrial disease remain 
undiagnosed. Finally, the statistical tools we have used in these analyses are currently limited. For 
example, MR ultimately relies on the availability of sufficient quantities of high quality eQTL data. 
However, as there is a future focus to; increase data-set sample size, report and characterize phenotypes 
such as AAO more accurately and continue to increase the number of identified mitochondrial disease 
and function genes, we will be able to further explore the role of specific mitochondrial processes in more 
detail and identify their distinct contribution to disease causation and progression.  
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In summary, in this study we provide robust evidence for the involvement of mitochondrial processes in 
sporadic PD, as opposed to its defined and well-established role in the monogenic forms of the disease. 
In relation to the 14 novel mitochondrial function genes that we have identified, our data suggests that it 
is not only mitochondrial quality control and homeostasis which contributes to PD risk but other key 
mitochondrial processes, such as the function of mitochondrial ribosomes, mirroring the biological 
complexity of mitochondrial disorders.  Thus, this study opens the way for the identification of novel drug 
targets in PD causation and progression. 
 
METHODS 
 
Samples and quality control of IPDGC datasets 
 
All genotyping data was obtained from IPDGC datasets, consisting of 41,321 individuals (18,869 cases and 
22,452 controls) of European ancestry. Detailed demographic and clinical characteristics are given in 
Supplementary Table 1 and are explained in further detail in along with detailed quality control (QC) 
methods6,35. For sample QC, in short, individuals with low call rate (<95%), discordance between genetic 
and reported sex,  heterozygosity outliers (F statistic cut-off of > -0.15 and < 0.15) and ancestry outliers 
(+/- 6 standard deviations from means of eigenvectors 1 and 2 of the 1000 Genomes phase 3 CEU and TSI 
populations from principal components 36) were excluded. Further, for genotype QC, variants with a 
missingness rate of > 5%, minor allele frequency < 0.01, exhibiting Hardy-Weinberg Equilibrium (HWE) < 
1E-5 and palindromic SNPs were excluded. Remaining samples were imputed using the Haplotype 
Reference Consortium (HRC) on the University of Michigan imputation server under default settings with 
Eagle v2.3 phasing based on reference panel HRC r1.1 201637,38. 
 
Curation of genes implicated in mitochondrial disorders and associated with mitochondrial function 
 
Gene lists were built to encompass different levels of evidence for involvement of the respective protein 
products in disease phenotypes that relate to mitochondrial function. The list of genes implicated in 
genetic mitochondrial disorders (“primary” gene list, n=196) has the most stringent criteria of evidence 
that the respective genes is related to mitochondrial dysfunction. It consists of 102 nuclear genes listed in 
MITOMAP (downloaded 2015) and 94 sourced from literature review as containing mutations that cause 
with mitochondrial disease.  
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The list of genes implicated in mitochondrial function (“secondary” gene list, n  = 1487) was constructed 
using the OMIM API to identify all genes for which the word “mitochondria” (or derivatives) appeared in 
the free-text description, and by combining this information with MitoCarta v2.0 genes with no OMIM 
phenotype. This therefore gathered a list of plausible biological candidate genes, i.e. genes that are 
functionally implicated in mitochondrial function and morphology for which we may lack genetic evidence 
for mitochondrial disease association. 
 
Next, to identify novel PD-associated genes, the 349 genes identified to be in LD with the PD risk variants 
of interest in the most recent PD meta-analysis (Nalls et al 2018) were removed from both lists (removed 
genes listed in Supplementary Table 2). The final “primary” and “secondary” gene lists are given in 
Supplementary Table 3 and Supplementary Table 4 and following the removal the PD-associated genes 
were n= 178 and n=1328 respectively. 
 
Cohort-level heritability estimates and meta analysis   
 
Genome-wide complex trait analysis (GCTA) was used to calculate heritability estimates for the four 
largest IPDGC cohorts (UK_GWAS, SPAIN3, NIA, and DUTCH) using non-imputed genotyping data for all 
variants within both mitochondria gene lists using the same workflow as 39. GCTA is a statistical method 
that estimates phenotypic variance of complex traits explained by genome-wide SNPs, including those not 
associated with the trait in a GWAS. Genetic relationship matrices were calculated for each dataset to 
identify the genetic relationship between pairs of individuals. Genetic relationship matrices were then 
input into restricted maximum likelihood analyses to produce estimates of the proportion of phenotypic 
variance explained by the SNPs within each subset of data. Principal components (PCs) were generated 
for each data-set using PLINK (version 1.9). In order to adjust for factors accounting to possible population 
substructure, the top twenty generated eigenvectors from the PC analysis, age, sex and prevalence were 
used as basic covariates. Disease prevalence standardized for age and gender based on epidemiological 
reports was specified at 0.00239–43. Summary statistics from these estimates were produced for all four 
datasets and were included in the meta-analyses. Random-effects meta-analysis using the residual 
maximum likelihood method, was performed using R (version 3.5.1) package metafor to calculate p-values 
and generate forest plots44.  
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Risk profiles versus disease status and age at onset 
 
Previous risk profiling methods have calculated polygenic risk scores (PRS) using only variants that exhibit 
genome-wide significant associated with disease risk. However, in the most recent PD meta analysis, it is 
shown that using variants at thresholds below genome-wide significance improves genetic predictions of 
disease risk (6,39).  Mirroring this workflow, but instead using only variants within gene regions outlined in 
both the primary and secondary gene lists, the R package PRsice2 was used to carry out PRS profiling in 
the standard weighted allele dose manner. In addition, PRsice2 performs permutation testing and p-value 
aware LD pruning to facilitate identifying the best p-value threshold for variant inclusion to construct the 
PRS. External summary statistics utilized in this phase of analysis included data from leave-one-out meta-
analyses (LOOMAs) that exclude the study in which the PRS was being tested, avoiding 
overfitting/circularity to some degree. LD clumping was implemented under default settings (window size 
= 250kb, r2 > 0.1) and for each dataset 10,000 permutations of phenotype-swapping were used to 
generate empirical p-value estimates for each GWAS derived p-value threshold ranging from 5E-08 to 0.5, 
at a minimum increment of 5E-08. Each permutation test in each dataset provided a Nagelkerke’s pseudo 
r2 after adjustment for an estimated prevalence of 0.005 and study-specific PCs 1-5, age and sex as 
covariates. GWAS derived p-value threshold with the highest pseudo r2 was selected for further analysis. 
Summary statistics were meta-analyzed using random effects (REML) per study-specific dataset using 
PRSice2 45. For the age at onset risk profiling, the same workflow was followed, however instead, age at 
onset was used as a continuous variable, as previously reported35 
 
Mendelian randomization to explore possible causal effect of mitochondria function genes  
MR uses genetic variants to identify if an observed association between a risk factor and an outcome is 
consistent with causal effect  46. This method has been implemented in several recent genetic studies to 
identify association between expression quantitative trait loci  (QTL), to more accurately nominate 
candidate genes within risk loci. Therefore, for this study, in the aim of identifying whether changes in 
expression of mitochondria function genes are potentially causally related to PD risk, two-sample MR was 
implemented. Both mitochondria gene lists were combined and all genes already associated with PD (i.e. 
that have been identified to be in LD with PD risk loci in the last meta-analysis) were removed, leaving 
1432 unique mitochondria function gene regions.   
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We utilized four large-scale  methylation and expression datasets  through the  summary-data-based 
Mendelian randomization (SMR) (http://cnsgenomics.com/software/smr) resource. Summary statistics 
were compared to PD outcome summary statistics for the mitochondria variants of interest (extracted 
from  4–6,29–33)  to identify possible association using the R package TwoSampleMR.   
Tissues were selected based on their relevance to the pathobiology of PD, which ultimately consisted of 
tissues from 10 brain regions , whole blood, skeletal muscle, and nerve, (a full list of the tissues utilised 
can be found in Supplementary Table 5). For the methylation QTLs “middle age” data was used, which 
was the the oldest available time point.  For each mitochondria function variant of interest (considered 
here the instrumental variable), wald ratios were generated for each variable that tagged a cis-QTL 
(probes within each gene and meeting a QTL p-value of at least 5E-08 in the original QTL study) and for a 
methylation or expression probe with a nearby gene. Using the default SMR protocols, linkage pruning, 
and clumping were implemented. Finally, for each dataset p-values were adjusted by false discovery rate 
to account for multiple testing. 
 
Co-expression network analysis  
 
Co-expression network analysis was used to determine whether mitochondrial genes associated with PD 
using the SMR analysis are co-expressed with genes associated with monogenic forms of PD in human 
brain. This analysis was performed by using GTEx V6 gene expression data (The GTEx Consortium et al. 
2015; Carithers et al. 2015) to generate co-expression networks for each of the 13 brain tissues included 
within the GTEx study. The raw FPKM (Fragments Per Kilobase of transcript per Million mapped reads) 
values were corrected for known batch effects, age at death, sex and post-mortem interval, as well as 
unknown effects. The unknown effects were detected with the Surrogate Variable Analysis (SVA) R 
Package (Leek and Storey 2007) and correction was performed using ComBat (Johnson, Li, and Rabinovic 
2007). The resulting residuals were used to create a signed network using the 
blockwiseConsensusModules R function from the WGCNA R package (Langfelder and Horvath 2008) for 
each of the 13 tissues. Next, the modules obtained in each of the 13 networks were assigned to cell types 
using the userListEnrichment R function implemented in the WGCNA R package, which measures 
enrichment between module-assigned genes and defined brain-related lists using a hypergeometric test. 
The same approach was used to annotate modules with Gene Ontology, REACTOME (Fabregat et al. 2018) 
and KEGG (Kanehisa et al. 2016) terms. 
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Expression-weighted cell-type enrichment (EWCE): evaluating enrichment of mitochondrial genes 
associated with PD risk 
 
Expression-weighted cell-type enrichment (EWCE) (https://github.com/NathanSkene/EWCE) (EWCE) was 
used to determine whether mitochondrial genes associated with PD using the MR analysis have higher 
expression within a particular cell type than expected by chance. The input for the analysis was  1) 
neuronal and glial clusters of the central nervous system (CNS) identified in the Linnarsson single-cell RNA 
sequencing dataset (amounting to a subset of 114 of the original 265 clusters identified) 
(http://mousebrain.org/) and 2) our list of mitochondrial genes highlighted through the MR analysis (see 
Supplementary Table 6 for the full list of Linnarsson CNS neuronal clusters used). 
 
For each gene in the Linnarsson dataset, cell-type specificity was estimated (the proportion of a gene’s 
total expression in one cell type compared to all cell types) using the ‘generate.celltype.data’ function of 
the EWCE package. EWCE with the target list was run with 100,000 bootstrap replicates, which were 
sampled from a background list of genes that excluded all genes without a 1:1 mouse: human ortholog.  
In addition, transcript length and GC-content biases were controlled for by selecting bootstrap lists with 
comparable properties to the target list. The analysis was performed using major cell-type classes (e.g. 
“telencephalon inhibitory interneurons”, “telencephalon projecting excitatory neurons”, etc.) and 
subtypes of these classes (e.g. TEINH6 [“Interneuron-selective interneurons, cortex/hippocampus”], 
TEINH7 [“Interneuron-selective interneurons, hippocampus”], etc.). Data are displayed as standard 
deviations from the mean, and any values < 0, which reflect a depletion of expression, are displayed as 0. 
P-values were corrected for multiple testing using the Benjamini-Hochberg method over all cell types and 
gene lists displayed.  
 
OMIM data  
 
Phenotype relationships and clinical synopses of all OMIM genes were downloaded from 
http://api.omim.org on the 29th of May 2018. OMIM genes were filtered to exclude provisional, non-
disease and susceptibility phenotypes retaining 2,898 unique genes that were confidently associated to 
4,034 Mendelian diseases. The phenotypic information relating to all genes associated with mitochondrial 
disorders was collated. 
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Figure 1. Workflow of mitochondrial-function specific PD analysis  
 
Figure 2. Forest plots of PRS for Parkinson’s Disease across cohorts.  
Random effect meta analysis results are shown as red diamonds and fixed effects are shown as blue, with 
the centerline of each diamond representing the summary PRS for that dataset.  
Figure 3. Forest plots of PRS for the age at onset of Parkinson’s Disease across cohorts.   
Random effect meta analysis results are shown as red diamonds and fixed effects are shown as blue, with 
the centerline of each diamond representing the summary PRS for that dataset.  
 
TABLES 
Table 1. Cohort level heritability analysis for the primary and secondary mitochondrial gene lists  
 Primary Secondary 
 Heritability estimate  SE of heritabilty estimate 
Heritability 
estimate  
SE of heritabilty 
estimate 
UK_GWAS 0.00321 0.00277 0.00563 0.00688 
SPAIN3 0.00027 0.00314 0.00629 0.00932 
NIA 0.00945 0.00540 0.03616 0.01365 
DUTCH 0.00000 0.00530 0.03562 0.01681 
 
 
Table 2. Summary of random-effects meta-analysis for the primary and secondary mitochondrial gene 
lists  
 
  
Heritability 
Estimate from 
random-effects 
Lower 95% 
confidence 
interval 
Upper 95% 
confidence 
interval 
P-value 
from 
random 
effects 
Heterogeneity of 
variance from 
random effects (%) 
Heterogeneity P-
value 
All SNPs 0.2313 0.1233 0.3393 2.72E-05 0.0100 3.00E-03 
Primary 0.0026 -0.0011 0.0062 1.66E-01 0.0000 4.85E-01 
Secondary 0.0167 0.0007 0.0328 4.10E-02 0.0001 9.63E-02 
Table 3. Significant functional associations of mitochondrial function genes via two-sample Mendelian 
randomization  
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Figure 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTARY  
 
Table S1. Demographic and clinical characteristics for all IPDGC genotyping data  
 
Table S2.  Mitochondrial genes identified to be in LD with the PD risk variants of interest in the most recent 
PD meta-analysis  that were removed from our list to identify novel association 
  
Table S3. Primary mitochondria gene list (hg/19) 
 
Table S4. Secondary mitochondria gene list (hg/19) 
 
Table S5. Tissues and data-sets included in Mendelian Randomisation analysis  
 
Table S6. List of the CNS cell clusters used for enrichment-weighted cell-type enrichment (EWCE) and 
results of EWCE analysis for all genes identified by two-sample Mendelian randomization  
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Table S7 Coexpression of genes identified using two-sample Mendelian randomization with genes known 
to cause familial forms of PD 
 
Table S8. Results of co-expression network analysis for all genes identified by two-sample Mendelian 
randomization  
 
Figure S1. Results of enrichment-weighted cell-type enrichment analysis for all genes identified by via 
two-sample Mendelian randomization  
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